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Background
Here we report on a Phase Ia clinical vaccine trial using
the AMA1 antigen from the blood-stage Plasmodium
falciparum malaria parasite. A variety of promising
‘mixed-modality’ regimens were tested, with all volun-
teers primed with chimpanzee adenovirus-ChAd63, and
then subsequently boosted with the orthopoxvirus MVA
and/or protein-in-adjuvant (Alhydrogel ± CPG 7909)
using 8 or 16 week prime-boost intervals. The induction
of high titre, neutralizing antibodies is deemed essential
for protection against blood-stage malaria. Peripheral
blood antibody secreting cells (ASC) and memory B
cells (mBC) play important roles in antibody production
and maintenance. Lymph node (LN) CD4+ follicular
helper T cells (Tfh cells) mediate cognate control of
antigen-specific antibody responses. Recently Tfh-like
cells have been found to be present in the CXCR5+ sub-
set of memory CD4+ T cells in human peripheral blood.
This facilitates analysis of the role of Tfh responses in
regulation of vaccine-elicited antibody responses,
although there is much debate over the relationship
between LN and circulating populations. Phenotypic
definition of the latter has also proved complex, with
recent studies indicating that phenotypically-distinct Tfh
populations with different functional profiles are elicited
by different antigenic stimuli. Characterizing T cell and
B cell populations across a variety of immunisation
regimes may lead to greater understanding of their value
as quantitative and qualitative predictors of antibody
responses.
Materials and methods
ASC and mBC responses were measured using a standar-
dized B cell ELISPOT method, using fresh and frozen
PBMC respectively, whilst antibody titre was measured
using a standardized ELISA for AMA1. Multiparameter
flow cytometry was also subsequently run using frozen
PBMC to characterise total peripheral CD4+ Tfh popula-
tions and the AMA1-specific CD4+ T cell response.
Results
AMA1 specific ASC, mBC and antibody responses fol-
lowed classical kinetics at a level comparable to those pre-
viously described, with ASC and antibody responses
strongly correlating. Notably, inclusion of CPG 7909
tended to lead to earlier detection of peripheral ASC
responses at day 4. The relationship between baseline Tfh
populations previously described as important in other
infections/vaccine regimens, as well as AMA1-specific
Tfh-like cells identifiable at post-boost time-points and
ASC/mBC/antibody responses is currently being
investigated.
Conclusions
Very few significant differences were observed between
groups with respect to ASC, mBC and antibody responses.
Responses primed with ChAd63 appear to boost compar-
ably whether or not CPG 7909 is included with the Alhy-
drogel adjuvant, though boosting with MVA trended
towards lower responses.
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